Worsening of Financial Well-Being Tied to Accelerated Cognitive Aging
via HealthDayWEDNESDAY, March 25, 2026 -- Declines in financial well-being during midlife and beyond may contribute to accelerated cognitive aging, according to a study published online March 16 in the American Journal of Epidemiology.
Katrina L. Kezios, Ph.D., from Boston University, and colleagues examined associations between changes in financial well-being and memory outcomes, using data from 7,676 adults (aged 50 years and older) participating in the Health and Retirement Study (2010 to 2020).
The researchers found that each 1-point worsening in average financial well-being was associated with poorer memory function (β = −0.009 standard deviation [SD]) and accelerated decline (β = −0.007 SD/year). The strongest associations were seen for participants with significant worsening of financial well-being and for those aged 65 years and older at baseline. Results persisted in sensitivity analyses.
"Our findings also point to potential policy implications," coauthor Adina Zeki Al Hazzouri, Ph.D., from Columbia University in New York City, said in a statement. "Income supports and financial assistance in later life may help protect cognitive health and reduce dementia risk, particularly for those experiencing financial decline."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-26 01:51
Read more
- Problem-Solving Strategy Boosts Mental Health in Young Adults With Cancer
- Update on FDA Advisory Committee Vote on Camizestrant in Combination with a CDK4/6 Inhibitor for Advanced HR-Positive Breast Cancer
- Mental Defeat Can Worsen Chronic Pain, Researchers Say
- Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Achieved Significant Weight Loss and Meaningful Metabolic Improvement in Phase III Trial
- CMS Extends Medicare's Short-Term Bridge Program for GLP-1 Obesity Drug Coverage
- Etavopivat is the First in a New Class of Drugs to Meet Both Co-Primary Endpoints in the Phase 3 HIBISCUS Trial, Substantially Reducing Vaso-Occlusive Crisis Events and Improving Hemoglobin Response in Sickle Cell Disease
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions